Companies · Pharmaceuticals

LP Investors, LLC

FAIRFIELD · Pharmaceuticals

Diligence memoA one-page analyst read on LP Investors, LLC — recommendation, valuation, rhythm, risks.
$40.0M
Total raised · real
1
Rounds
Latest step-up
Top 23%
Sector rank · raised
Series B
Latest stage · inferred · Thu Dec 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

LP Investors, LLC looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.00× the median modeled value of Series B Pharmaceuticals companies in 2016–2018 (40 peers) — value vs value, same stage and era.
Dormant
  • Last raise 8.5 yr ago; this sector typically re-raises about every 13 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

LP Investors, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
8.5 yr record
Peak capital year was 2017 with $40.0M across 1 filings.
Market position
ahead of 78% of Pharmaceuticals peers
Capital scale is ahead of 78% of Pharmaceuticals peers; modeled value is above 92% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2017: $40.0M across 1 filings.
  • Largest single filing was $40.0M on 2017-12-28.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
  • The more important signal is lifecycle: repeated filings ended years ago, so current activity needs outside confirmation.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Pharmaceuticals

LP Investors, LLC is one of 1613 Pharmaceuticals companies tracked from FAIRFIELD. By capital raised it ranks in the upper tier (ahead of 78% of sector peers), and among the largest by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
32
Investors (latest)
2014
Year incorporated
2017-12-28
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500M$1.0B$1.5B$2.0BSeries B · 2017-12-28 Raised $40M (real) Modeled valuation $1.4B (est)$40M$1.4BSeries B2017

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series B$40.0M · 2017

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed, Series A — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 25%.

Modeled valuation trajectory
$1.4B
Base estimate est.
$84.0M
Conservative case
$5.2B
Upside case
$222.2M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
57%
Survival probability
38% low · 70% high
1.49×/yr
Annual markup
1.80×/yr upside case
6.0 yr
Elapsed time used
8.5 yr actual, capped for stale marks
pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
8.5 yr
On record since
2017
First round
1
Rounds on file
How it compares to the market

Benchmarked against 1613 companies in Pharmaceuticals. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 4.9× above median
This company$40.0M
Sector median$8.1M
Latest round — vs other Series B rounds in sector (real $, this stage) 2.2× above median
This company$40.0M
Sector median$18.0M
Modeled value — vs sector median (estimate, all stages) 18× above median
This company$1.4B
Sector median$76.1M

Raised more than 78% of sector peers (real $). Modeled value above 92% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #1 of 40.

This companyCohort peer
$100.0M$1.0B$10.0B$10.0M$100.0MCapital raised (log)GigaGen, Inc. · Series B Raised $36.1M · modeled $1.2B (est)Vitality Biopharma, Inc. · Series B Raised $39.5M · modeled $1.2B (est)Madrigal Pharmaceuticals, Inc. · Series B Raised $35.0M · modeled $1.2B (est)Slayback Pharma Ltd Liability Co · Series B Raised $35.0M · modeled $1.2B (est)X4 Pharmaceuticals, Inc. · Series B Raised $73.2M · modeled $1.2B (est)Lumos Pharma, Inc. · Series B Raised $53.5M · modeled $1.2B (est)Innovate Biopharmaceuticals Inc. · Series B Raised $42.7M · modeled $1.1B (est)SteadyMed Ltd. · Series B Raised $51.3M · modeled $1.0B (est)Stargazer Pharmaceuticals, Inc. · Series B Raised $28.5M · modeled $967.8M (est)St Renatus Llc · Series B Raised $33.1M · modeled $884.1M (est)Bellerophon Therapeutics, Inc. · Series B Raised $25.0M · modeled $796.9M (est)LP Investors, LLC (this company) Raised $40.0M · modeled $1.4B (est)LP Investors, LLC
CompanyStageRaised · realValue · estvs peer med.
LP Investors, LLC this companySeries B$40.0M$1.4B2.00×
GigaGen, Inc.Series B$36.1M$1.2B1.81×
Vitality Biopharma, Inc.Series B$39.5M$1.2B1.80×
Madrigal Pharmaceuticals, Inc.Series B$35.0M$1.2B1.75×
Slayback Pharma Ltd Liability CoSeries B$35.0M$1.2B1.75×
X4 Pharmaceuticals, Inc.Series B$73.2M$1.2B1.75×
Lumos Pharma, Inc.Series B$53.5M$1.2B1.70×
Innovate Biopharmaceuticals Inc.Series B$42.7M$1.1B1.64×
SteadyMed Ltd.Series B$51.3M$1.0B1.50×
Stargazer Pharmaceuticals, Inc.Series B$28.5M$967.8M1.42×
St Renatus LlcSeries B$33.1M$884.1M1.30×
Bellerophon Therapeutics, Inc.Series B$25.0M$796.9M1.17×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series B$40.0M2017-12-28$222.2M$1.4B90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series B$40.0M2017-12-28
    • First recorded raise — entered as Series B.
    • 32 investors on this round.
Intelligence
Modeled next raise
$64.0M
Modeled next size est.range $41.6M$102.4M
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
RONALD GOLD2 other2017-12
Nikhil Puri1 other2017-12
Christopher Semple2017-12
David M. Seltzer2017-12
Rasik Gondalia2017-12
Steven M. Goldman2017-12
Registry & provenance

LP Investors, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1727992
SEC CIK
2014
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Delex Healthcare Group, Inc.PharmaceuticalsSeries B$40.0M$341.1Msame sector · same stage
LSK BioPartners, Inc.PharmaceuticalsSeries B$40.0M$680.1Msame sector · same stage
Vensun Pharmaceuticals, Inc.PharmaceuticalsSeries B$39.9M$663.1Msame sector · same stage
Ra Pharmaceuticals, Inc.PharmaceuticalsSeries B$39.6M$994.6Msame sector · same stage
XTuit Pharmaceuticals, Inc.PharmaceuticalsSeries B$39.5M$748.7Msame sector · same stage
Evolus, Inc.PharmaceuticalsSeries B$40.5M$1.4Bsame sector · same stage
Vitality Biopharma, Inc.PharmaceuticalsSeries B$39.5M$1.2Bsame sector · same stage
Nupathe Inc.PharmaceuticalsSeries B$39.2M$952.1Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Med-Tech Investments Group, LLCPharmaceuticalsSeed$98.9M84%
Lb Pharmaceuticals IncPharmaceuticalsSeries D+$1.5B82%
LGM Holdings, LLCPharmaceuticalsSeed$35.3M82%
Blc Usa LpPharmaceuticalsPre-Seed$38.5M81%
Supreme Pharmaceuticals Inc.PharmaceuticalsSeed$14.1M80%
Fastball Capital Group, LlcPharmaceuticalsPre-Seed$35.5M80%
ACON Injectable Investors I, L.P.PharmaceuticalsSeries C$1.5B80%
PharmID, Inc.PharmaceuticalsSeries A$154.9M80%
Frequently asked
How much funding has LP Investors, LLC raised?
LP Investors, LLC has raised approximately $40.0M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is LP Investors, LLC's estimated valuation?
Provath's modeled valuation for LP Investors, LLC is approximately $1.4B (modeled range $84.0M–$5.2B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is LP Investors, LLC at?
LP Investors, LLC's latest modeled financing stage is Series B. Its most recent recorded round closed around Thu Dec 28.
What does LP Investors, LLC do and where is it based?
LP Investors, LLC operates in the Pharmaceuticals sector, based in FAIRFIELD.
Explore related

See where LP Investors, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at LP Investors, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.